Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01550328 · ClinicalTrials.gov registry record
Bias Source of Signal in SCOUT DS
A clinical trial, sponsored by VeraLight.
- Terminated
- Registry status
- 25
- Enrollment target
NCT01550328: Clinical Trial study, sponsored by VeraLight.
NCT01550328 is a clinical trial that was terminated before completion, run by VeraLight. The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01550328 was terminated before completion, sponsored by VeraLight.
- TERMINATED
- Registry status
- 25 participants
- Enrollment target
Study Summary
The primary objective is to identify device characteristics, components or subsystems that manifest as screening score bias in SCOUT DS.
Primary Outcome
The primary objective of this study is to identify device characteristics, components, or subsystems that manifest as screening score bias in SCOUT DS. The study will switch subsystems between devices and if the bias differs by more than 3.5 Diabetes Risk Score units compared to the baseline score, we would conclude that the bias was contained within that particular subsystem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2012-04 |
| Est. Completion | 2013-01 |
Why NCT01550328 stopped before completion
NCT01550328 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 25 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01550328 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01550328 about?
NCT01550328 is a clinical study titled "Bias Source of Signal in SCOUT DS". The primary objective is to identify device characteristics, components or subsystems that manifest as screening score bias in SCOUT DS.
What is the current status of trial NCT01550328?
This trial is currently terminated. The enrollment target is 25 participants. The study started on 2012-04. Estimated completion is 2013-01.
Who is sponsoring clinical trial NCT01550328?
This trial is sponsored by VeraLight, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia